Tokyo Tape
Sign in
← Nipro

Quarterly report · Q2

8086.TEDINET S100S9GB
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥285.9bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥545.2bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥260.3bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥13.5bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥6.4bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥14.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥15.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥17.5bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥13.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥9.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥10.4bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥7.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.10Tat 2023-09-30Cons.Assets
Total assets¥1.03Tat 2023-03-31Cons.Assets
Total assets¥1.01Tat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥821.8bnat 2023-09-30Cons.Liabilities
Total liabilities¥785.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥274.0bnat 2023-09-30Cons.Net assets
Net assets / equity¥242.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥237.2bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥87.2bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥89.7bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥83.8bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥84.7bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥89.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.1bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥18.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥10.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥35.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥71.7bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥41.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥8.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥43.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥23.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥60.892023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥35.762023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.052022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥5.992022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥53.952023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥24.852022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥33.972022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio21.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio20.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio22.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥2.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥417m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥109m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥36.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥36.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥14.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥223.6bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥220.2bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥22.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥62.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥35.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥27.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.7bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2023-04-01 → 2023-09-30¥33.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.4bn
—segment totalrevenue2023-04-01 → 2023-09-30¥319.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥285.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥34.0bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥27.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥321.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥285.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥36.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥27.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥2.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥340m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥168m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥15.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥203.9bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥200.8bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥44.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥34.1bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10.8bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥849m
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-09-30¥28.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-09-30¥25.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
—segment totalrevenue2022-04-01 → 2022-09-30¥276.8bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥260.0bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥16.8bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥21.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥278.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥260.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥18.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥21.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 644
ItemContextValueUnit
Foreign exchange gains noiCurrentYTDDuration3604000000JPY
Other noiPrior1YTDDuration1015000000JPY
Other noiCurrentYTDDuration1259000000JPY
Non operating incomePrior1YTDDuration8813000000JPY
Non operating incomeCurrentYTDDuration6061000000JPY
Interest expenses noePrior1YTDDuration2023000000JPY
Interest expenses noeCurrentYTDDuration2847000000JPY
Equity in losses of affiliates noePrior1YTDDuration629000000JPY
Equity in losses of affiliates noeCurrentYTDDuration949000000JPY
Other noePrior1YTDDuration928000000JPY
Other noeCurrentYTDDuration1017000000JPY
Non operating expensesPrior1YTDDuration3581000000JPY
Non operating expensesCurrentYTDDuration4813000000JPY
Ordinary incomePrior1YTDDuration11604000000JPY
Ordinary incomeCurrentYTDDuration14736000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration2232000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration812000000JPY
Gain on sales of investment securities eiPrior1YTDDuration219000000JPY
Gain on sales of investment securities eiCurrentYTDDuration3682000000JPY
State subsidy eiPrior1YTDDuration－JPY
State subsidy eiCurrentYTDDuration367000000JPY
Other eiPrior1YTDDuration50000000JPY
Other eiCurrentYTDDuration251000000JPY
Extraordinary incomePrior1YTDDuration2502000000JPY
Extraordinary incomeCurrentYTDDuration5112000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration161000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration306000000JPY
Dispute costs elPrior1YTDDuration272000000JPY
Dispute costs elCurrentYTDDuration146000000JPY
Expenses for suspension of operation elPrior1YTDDuration320000000JPY
Expenses for suspension of operation elCurrentYTDDuration－JPY
Loss on sale of investment in affiliated companies elPrior1YTDDuration－JPY
Loss on sale of investment in affiliated companies elCurrentYTDDuration1605000000JPY
Other elPrior1YTDDuration206000000JPY
Other elCurrentYTDDuration334000000JPY
Extraordinary lossPrior1YTDDuration961000000JPY
Extraordinary lossCurrentYTDDuration2393000000JPY
Income before income taxesPrior1YTDDuration13145000000JPY
Income before income taxesCurrentYTDDuration17455000000JPY
Income taxes currentPrior1YTDDuration6306000000JPY
Income taxes currentCurrentYTDDuration7242000000JPY
Income taxes deferredPrior1YTDDuration-211000000JPY
Income taxes deferredCurrentYTDDuration-197000000JPY
Income taxesPrior1YTDDuration6094000000JPY
Income taxesCurrentYTDDuration7044000000JPY
Profit lossPrior1YTDDuration7051000000JPY
Profit lossCurrentYTDDuration10410000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration798000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration479000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration6252000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass